MedPath

Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

Phase 4
Completed
Conditions
Healthy
Registration Number
NCT00344955
Lead Sponsor
Regional Hospital Holstebro
Brief Summary

We wanted to test the acute effect of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Both men and women
  • Age: Between 20-50
  • BMI<30
Exclusion Criteria
  • Clinical signs or history of disease of heart, lungs, kidneys or endocrine organs.
  • Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose)
  • Albuminuria or glucosuria
  • Cancer
  • Art. hypertension
  • Alcohol abuse
  • Medical treatment, except oral contraceptives
  • Pregnancy or breast feeding
  • Blood donation less than 1 month before study

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
GFR
RPF
FEna
FELi
CLna
CLli
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Medical Research

🇩🇰

Holstebro, Denmark

© Copyright 2025. All Rights Reserved by MedPath